<><><>
[HTML] What Do We Need to Know About Rising Rates of Idiopathic Pulmonary Fibrosis? A Narrative Review and Update
JV Pergolizzi, JA LeQuang, M Varrassi, F Breve… - Advances in Therapy, 2023
… The most common type of idiopathic interstitial pneumonia is idiopathic
pulmonary fibrosis (IPF), … With few geographical exceptions, IPF is a rare disease
but its prevalence has been … Idiopathic pulmonary fibrosis (IPF), the most common …
- 特発性肺線維症の発症率の上昇について知っておくべきことは? 物語のレビューとアップデート
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF)
G Sgalla, J Simonetti, S Cortese, L Richeldi - Expert Opinion on Investigational Drugs, 2023
Introduction The two available therapies for idiopathic pulmonary fibrosis (IPF),
pirfenidone and nintedanib, slow down but do not halt IPF progression. Therefore,
several agents with specific molecular targets have been recently investigated to …
- BI 1015550: 特発性肺線維症 (IPF) における肺機能低下に対する研究中のホスホジエステラーゼ 4B (PDE4B) 阻害剤
[HTML] MicroRNA expression in fibroblastic foci within idiopathic pulmonary fibrosis lungs reveals novel disease relevant pathways
L Sabater, JB Gossart, I Hernandez, D Rico… - The American Journal of …, 2023
… with profibrotic processes in idiopathic pulmonary fibrosis (IPF). However, most of
these studies used whole IPF tissue or in vitro … in IPF, then isolate miRs and
compare their expression levels to those found in whole IPF lung tissue and/or in …
- 特発性肺線維症肺内の線維芽細胞病巣におけるマイクロRNA発現は、新規疾患関連経路を明らかにする
[HTML] C-type lectin Mincle initiates IL-17-mediated inflammation in acute exacerbations of idiopathic pulmonary fibrosis
C Tao, H Xian, Z Nian-yu, S Jia-cui, W Dong… - Biomedicine & …, 2023
… idiopathic pulmonary fibrosis (AE-IPF) has a poor prognosis and high mortality.
However, there is limited information regarding the mechanisms of AE-IPF…
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic …
- C型レクチンミンクルは、特発性肺線維症の急性増悪においてIL-17を介した炎症を引き起こす
[HTML] Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
T Ogura, Y Inoue, A Azuma, S Homma, Y Kondoh… - Advances in Therapy, 2023
… the treatment of idiopathic pulmonary fibrosis (IPF); however, treatment
discontinuation due to adverse events (AEs) is common. A large-scale post-marketing
surveillance study is investigating the real-world tolerability/safety of nintedanib in …
- 特発性肺線維症患者におけるニンテダニブの実際の安全性と忍容性：市販後の中間報告
[HTML] Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
MA Khan, N Sherbini, S Alyami, A Al-Harbi… - Annals of Thoracic Medicine, 2023
… Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial
pneumonia that causes fibrosis with scarring of the lungs from an unknown cause,
though the exact mechanisms of damage in IPF remain poorly understood. It is …
- リヤドのキング・アブドゥルアズィーズ・メディカル・シティにおける特発性肺線維症に対するニンテダニブとピルフェニドン：実際のデータ
[PDF] Deciding a Treatment Plan for an Older Patient With Severe Idiopathic Pulmonary Fibrosis: A Case Report
Y Akashi, Y Horinishi, C Sano, R Ohta - Cureus Journal of Medical Science, 2023
… of IPF in older patients can facilitate the discussion of advanced care planning
and palliative care. We discuss treatment plans for idiopathic … The treatment of IPF
in older patients with immunosuppressants is controversial in palliative care. Current …
- 重度の特発性肺線維症の高齢患者の治療計画の決定: 症例報告
[PDF] Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. Cells 2022, 11, 1626
M Korfei, P Mahavadi, A Guenther - State of the Art in Idiopathic Pulmonary Fibrosis, 2022
… Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung
disease with limited … has emerged as crucial mediators of IPF pathogenesis.
HDACs deacetylate histones and result … In IPF, induction and abnormal …
- 特発性肺線維症におけるヒストン脱アセチル化酵素の標的化：将来の治療選択肢。
[PDF] αvβ6 Integrin Positron Emission Tomography of Lung Fibrosis in Idiopathic Pulmonary Fibrosis and Long-COVID
RH Kimura, H Sharifi, B Shen, GJ Berry, HH Guo - American Journal of Respiratory …, 2023
COVID. Maximal intensity projection images from αvβ6 integrin PET-CT of healthy
volunteer (A), patient with IPF, with basilar peripheral predominant pattern of uptake
corresponding to areas of fibrosis (B), and long-COVID patient 12 months after …
- 特発性肺線維症およびLong-COVIDにおける肺線維症のαvβ6インテグリン陽電子放出断層撮影
[PDF] State of the Art in Idiopathic Pulmonary Fibrosis. Cells 2022, 11, 2487
E El Agha, M Wygrecka - State of the Art in Idiopathic Pulmonary Fibrosis, 2022
… Idiopathic pulmonary fibrosis (IPF) is a form of usual interstitial pneumonia (UIP),
though its origin is unknown. IPF remains one of the most … related to the
pathophysiological events that lead to the formation of fibrotic scars in the lungs of …
- 特発性肺線維症の最先端
23/01/26
[HTML] Artificial neural network identified the significant genes to distinguish Idiopathic pulmonary fibrosis
Z Li, S Wang, H Zhao, P Yan, H Yuan, M Zhao, R Wan… - Scientific Reports, 2023
… The current diagnosis of IPF is complex and usually completed by a
multidisciplinary team including clinicians, radiologists and … novel practical
methods for IPF diagnosis. This study provided a new diagnostic model of idiopathic …
- 人工ニューラルネットワークは、特発性肺線維症を区別するための重要な遺伝子を特定
[HTML] MicroRNA expression in fibroblastic foci within idiopathic pulmonary fibrosis lungs reveals novel disease relevant pathways
L Sabater, JB Gossart, I Hernandez, D Rico… - The American Journal of …, 2023
… with profibrotic processes in idiopathic pulmonary fibrosis (IPF). However, most of
these studies used whole IPF tissue or in vitro … in IPF, then isolate miRs and
compare their expression levels to those found in whole IPF lung tissue and/or in …
- 特発性肺線維症肺内の線維芽細胞病巣におけるマイクロRNA発現は、新規疾患関連経路を明らかにする
[HTML] Pregnancy in a Patient with Idiopathic Pulmonary Fibrosis: A Case Report
R Horgan, Z Kassem, G Too, A Abuhamad, S Warsof - American Journal of …, 2023
… Idiopathic pulmonary fibrosis (IPF) is a progressive restrictive lung disease. Data
on the impact of pregnancy on IPF and maternal outcome is extremely limited. We
present the case of a 35-year-old woman, gravida 1 para 0 with familial IPF with no …
- 特発性肺線維症患者の妊娠：症例報告
[HTML] C-type lectin Mincle initiates IL-17-mediated inflammation in acute exacerbations of idiopathic pulmonary fibrosis
C Tao, H Xian, Z Nian-yu, S Jia-cui, W Dong… - Biomedicine & …, 2023
… idiopathic pulmonary fibrosis (AE-IPF) has a poor prognosis and high mortality.
However, there is limited information regarding the mechanisms of AE-IPF…
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic …
- C型レクチンミンクルは、特発性肺線維症の急性増悪においてIL-17を介した炎症を引き起こす
[PDF] Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. Cells 2022, 11, 1626
M Korfei, P Mahavadi, A Guenther - State of the Art in Idiopathic Pulmonary Fibrosis, 2022
… Abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung
disease with limited … has emerged as crucial mediators of IPF pathogenesis.
HDACs deacetylate histones and result … In IPF, induction and abnormal …
- 特発性肺線維症におけるヒストン脱アセチル化酵素の標的化：将来の治療選択肢。
[PDF] State of the Art in Idiopathic Pulmonary Fibrosis. Cells 2022, 11, 2487
E El Agha, M Wygrecka - State of the Art in Idiopathic Pulmonary Fibrosis, 2022
… Idiopathic pulmonary fibrosis (IPF) is a form of usual interstitial pneumonia (UIP),
though its origin is unknown. IPF remains one of the most … related to the
pathophysiological events that lead to the formation of fibrotic scars in the lungs of …
- 特発性肺線維症の最先端
[HTML] Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
T Niitsu, K Fukushima, S Komukai, S Takata, Y Abe… - RMD Open, 2023
… ILD (PF-ILD) or progressive pulmonary fibrosis,2 which has a prognosis as poor
as that of idiopathic pulmonary fibrosis (IPF).3 This phenotype is … The antifibrotic
agent nintedanib was recently approved for the treatment of ILD with progressive …
- 進行性線維化性間質性肺疾患患者の予後に対する抗線維薬の実際の影響
Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo …
T Xiao, S Ren, J Bao, D Gao, R Sun, X Gu, J Gao… - European Journal of …, 2023
… Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease, and its 5-year mortality
rate is even higher than the mortality rate of some … To determine the role of
Vorapaxar in pulmonary fibrosis in vivo, a pulmonary fibrosis model was established …
- Vorapaxar は、PAR1/JAK2/STAT1/3 シグナル伝達経路に介入することにより、肺線維症の有望な候補であることが証明されました - 実験的な in vitro および vivo 研究
Real-world utility of a genomic classifier in establishing a diagnosis of newly identified interstitial lung disease
M Abdalla, C Castellani, H Singh, JS Kurman, BS Benn - Respiratory Medicine and …, 2023
… Idiopathic pulmonary fibrosis (IPF) is a specific form of progressive, fibrosing
interstitial pneumonia of unknown etiology. The diagnosis requires identification of a
usual interstitial pneumonia (UIP) pattern on chest high-resolution computerized …
- 新たに同定された間質性肺疾患の診断確立におけるゲノム分類子の実世界での有用性
Delineating associations of progressive pleuroparenchymal fibroelastosis in patients with pulmonary fibrosis
E Gudmundsson, A Zhao, N Mogulkoc, A Wells… - ERJ Open Research, 2022
… in idiopathic pulmonary fibrosis (IPF). We examined mortality associations of
longitudinal change in computer quantified PPFE-like lesions in IPF and … Methods:
two CT scans 6-36 months apart were retrospectively examined in one IPF (n=414) …
- 肺線維症患者における進行性胸膜実質線維弾性症の関連の描写
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
癒しの音楽をお届けいたします。
###
